We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

Scientific Publication

0

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the development of ‘mucosal protectors’. These agents form a bioprotective film in the gastrointestinal tract and potentially may prevent microorganisms from crossing the mucus barrier. To date, the most widely studied substances include xyloglucan (Xilaplus®) and gelatin tannate (Tasectan®, Gelenterum®). 2 new clinical studies are about to start to increase the body of evidence of those substances. Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Read more

New Scientific publication on TASECTAN® DUO

Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25.

Pathogenic microorganisms can adhere to the intestinal mucosa and influence cellular tight-junction function, leading to diarrhea. In an in vitro study, it was compared the protective efficacy of a combination of gelatine tannate plus inactivated probiotic (Tasectan® Duo) with that of other widely used antidiarrheal agents (Diosmectite, Saccharomyces boulardii, and a probiotic mixture). The study results clearly show that the protective efficacy of Tasectan® Duo manifests early and is maintained for 24 h. This effect is quicker and lasts longer that with the other compounds evaluated. These data further reinforce the potential broad utility of Tasectan® Duo in the management of diarrhea of several causes (e.g., infectious gastroenteritis, antibiotic therapy and chemotherapy) in population groups of all ages. Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25. doi: 10.2217/fmb-2016-0195.

Read more

The role of mucoprotectants in the management of gastrointestinal disorders.

Eutamene, Beaufrand Harkat C, Theodorou V.

“The new mucoprotectants, such as gelatin tannate and xyloglucan, have the ability to protect the intestinal mucosa and to exert anti-diarrheal effects. In the future the ability of these substances to enhance the intestinal barrier may extend their use in the management of a variety of gastro-intestinal diseases associated with ‘leaky gut’.

Read more

Let's meet in..

2018, Mar 16

EAU 18

EAU copenhagen 2018
Read more

2018, May 09

ESPGHAN 51

ESPGHAN geneva 2018
Read more

2018, May 19

IBS DAYS

Read more

2018, May 26

EAACI 2018

Read more

2018, Aug 29

FNM 2018

FNM-2018-Amsterdam
Read more